Cite
HARVARD Citation
Hirata, K. et al. (2021). A long-term open-label safety study of galcanezumab in Japanese patients with migraine. Expert opinion on drug safety. 20 (6), pp. 721-733. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Hirata, K. et al. (2021). A long-term open-label safety study of galcanezumab in Japanese patients with migraine. Expert opinion on drug safety. 20 (6), pp. 721-733. [Online].